PDCD1 and small cell lung carcinoma: In renal cell carcinoma, small cell lung cancer and melanoma, the microbiota can alter the response to immunotherapy via antibodies targeting programmed cell death protein-1 (PD-1) or its ligand (PDL-1) [17–19].